{"entity":{"id":"nct06075264","kind":"trial","name":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","aka":[],"tldr":"A phase 2 trial of Artesunate ointment in vulvar cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.","summary":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) is a phase 2 interventional study registered as NCT06075264 by Frantz Viral Therapeutics, LLC, with 27 participants planned, started 2023-12-06 and due to reach its primary completion in 2026-12. Interventions recorded: Artesunate ointment and Placebo ointment.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06075264","url":"https://clinicaltrials.gov/study/NCT06075264"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["vulvar","hpv-associated-vulvar-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["frantz-viral-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06075264","phase":"2","setting":"A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)","sponsor":"Frantz Viral Therapeutics, LLC","started":"2023-12-06","startedType":"actual","enrolled":27,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06075264/","neighbours":{"cancer":[{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"company":[{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","route":"/companies/frantz-viral-therapeutics/"}]}}